Dr. Mark Kirchhof reports late breakers presentations around atopic dermatitis and prurigo nodularis from the 2023 EADV Congress in Berlin.

Dr. Mark Kirchhof discusses the late breaker presentations about HS and alopecia areata at the 2023 EADV Congress.

Dr. Mark Kirchoff reports lives from the 2023 EADV Congress in Berlin and gives insights into the pathogenesis of psoriasis.

Dupilumab successfully decreases IgE serum levels in AD patients regardless of dosing intervals, according to a recent study.

Risankizumab is effective at achieving skin clearance in moderate-to-severe plaque psoriasis in bio-naive patients.

Race an ethnicity may not be associated with access to biologics for psoriasis patients in the United States.

A maternal high protein diet may be a risk factor for infantile AD during the first year of life.

Psoriasis and AD patients may have differing views on disease severity, a phenomenon known as discordant severity grading.